001     1027028
005     20250204113901.0
024 7 _ |a 10.1093/neuonc/noae032
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a 10.34734/FZJ-2024-03594
|2 datacite_doi
024 7 _ |a 38598668
|2 pmid
024 7 _ |a WOS:001229686400001
|2 WOS
037 _ _ |a FZJ-2024-03594
082 _ _ |a 610
100 1 _ |a Nayak, Lakshmi
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review
260 _ _ |a Oxford
|c 2024
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718108908_30832
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors.Methods: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and cerebrospinal fluid (CSF)-liquid biopsy in CNS lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL).Results: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, and steroid responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments, and prediction of outcome.Conclusions: Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.Keywords: CSF biomarkers; MYD88 mutations; circulating tumor DNA; primary CNS lymphomas; secondary CNS lymphomas
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Bettegowda, Chetan
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Scherer, Florian
|0 0000-0001-9635-5487
|b 2
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 3
700 1 _ |a Ahluwalia, Manmeet
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Baraniskin, Alexander
|0 P:(DE-HGF)0
|b 5
700 1 _ |a von Baumgarten, Louisa
|0 0000-0002-6634-0927
|b 6
700 1 _ |a Bromberg, Jacoline E C
|0 0000-0002-3830-7142
|b 7
700 1 _ |a Ferreri, Andrés J M
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Grommes, Christian
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Hoang-Xuan, Khê
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Kühn, Julia
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Rubenstein, James L
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Rudà, Roberta
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Weller, Michael
|0 0000-0002-1748-174X
|b 14
700 1 _ |a Chang, Susan M
|0 P:(DE-HGF)0
|b 15
700 1 _ |a van den Bent, Martin J
|0 0000-0001-5710-5127
|b 16
700 1 _ |a Wen, Patrick Y
|0 0000-0002-0774-7700
|b 17
700 1 _ |a Soffietti, Riccardo
|0 0000-0002-9204-7038
|b 18
|e Corresponding author
773 _ _ |a 10.1093/neuonc/noae032
|g Vol. 26, no. 6, p. 993 - 1011
|0 PERI:(DE-600)2094060-9
|n 6
|p 993 - 1011
|t Neuro-Oncology
|v 26
|y 2024
|x 1522-8517
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/1027028/files/PDF.pdf
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/1027028/files/noae032.pdf
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/1027028/files/PDF.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/1027028/files/PDF.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/1027028/files/PDF.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/1027028/files/PDF.jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/1027028/files/noae032.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/1027028/files/noae032.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/1027028/files/noae032.jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/1027028/files/noae032.jpg?subformat=icon-1440
909 C O |o oai:juser.fz-juelich.de:1027028
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2024-12-11
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21